{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:42:07Z","timestamp":1778503327557,"version":"3.51.4"},"reference-count":28,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100016223","name":"Wilmot Cancer Institute","doi-asserted-by":"publisher","award":["P30CA272302"],"award-info":[{"award-number":["P30CA272302"]}],"id":[{"id":"10.13039\/100016223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Hematological toxicities are a common sequelae of radiation therapy (RT), and pelvic RT is of particular concern as the pelvic marrow contributes nearly 50% of total body hematopoiesis. We evaluated the impact of pelvic RT on hematological toxicities in pediatric patients with pelvic genitourinary rhabdomyosarcoma (GU-RMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A secondary evaluation of 448 pediatric patients (53.8% male) with intermediate-risk RMS in the ARST0531 trial included 65 with pelvic GU-RMS (who received pelvic RT). Multivariable logistic regression was used to compare cytopenias and complications (febrile neutropenia, infectious complications) between GU-RMS and non-GU-RMS. Primary analysis assessed toxicities over the study period (weeks 1\u201343), with secondary analysis evaluating T1 (weeks 1\u201315), T2 (weeks 16\u201330), and T3 (weeks 31\u201343).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      GU-RMS patients did not have a significantly higher risk of cytopenias than non-GU RMS patients. Neutropenia was the most common, affecting 79.4% of subjects, with no significant difference between the GU (73.8%) and non-GU (80.4%) groups (OR 0.64, 95% CI 0.34\u20131.19,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.16). Anemia rates were similar in the GU (36.9%;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200924) and non-GU (35.2%;\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u2009135) groups (OR 0.96, 95% CI 0.54\u20131.70,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.89). Thrombocytopenia occurred slightly more often in the GU group (33.8%) than the non-GU group (28.4%) but was not statistically significant (OR 1.49, 95% CI 0.81\u20132.73,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.20). Pelvic RT for GU-RMS in T1 was linked to a significantly higher risk of thrombocytopenia compared to non-GU subjects (OR 2.79, 95% CI 1.25\u20136.23, p\u2009=\u20090.01), which declined over time (T2, T3). Rates of febrile neutropenia (3.1%\u20139.2%) and infectious complications (4.6%\u201315.4%) in GU patients did not differ significantly from those in non-GU cohorts (febrile neutropenia: 7.3%\u201313.05%; infectious complications: 5.5%\u20139.7%) across T1\u2013T3.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Hematological toxicities were comparable between pediatric GU and non-GU RMS patients. Pelvic RT for GU-RMS increased the risk of early thrombocytopenia, which diminished over time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03915603251347441","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T03:06:33Z","timestamp":1750993593000},"page":"741-748","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of pelvic radiotherapy on hematological toxicities in pediatric genitourinary rhabdomyosarcoma"],"prefix":"10.1177","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-8987","authenticated-orcid":false,"given":"Kamil","family":"Malshy","sequence":"first","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Health Services Research and Policy, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor C","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy D","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Steidle","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Fairbourn","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Kucherov","sequence":"additional","affiliation":[{"name":"Pediatric Urology \u2013 Golisano Children\u2019s Hospital, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jathin","family":"Bandari","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Rochester Medical Center, Rochester, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102864"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28748"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2016.05.012"},{"key":"e_1_3_3_5_2","unstructured":"Children\u2019s Oncology Group. https:\/\/www.childrensoncologygroup.org\/about (accessed 9 June 2025)."},{"key":"e_1_3_3_6_2","unstructured":"Children\u2019s Oncology Group. Combination chemotherapy and radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. https:\/\/clinicaltrials.gov\/study\/NCT00354835?term=NCT00354835&rank=1 (accessed 9 June 2025)."},{"key":"e_1_3_3_7_2","unstructured":"Children\u2019s Oncology Group. Vincristine dactinomycin and cyclophosphamide with or without radiation therapy in treating patients with newly diagnosed low-risk rhabdomyosarcoma. https:\/\/clinicaltrials.gov\/study\/NCT00075582?term=NCT00075582&rank=1 (accessed 9 June 2025)."},{"key":"e_1_3_3_8_2","unstructured":"Children\u2019s Oncology Group. High-dose combination chemotherapy and radiation therapy in treating patients with newly diagnosed metastatic rhabdomyosarcoma or ectomesenchymoma. https:\/\/clinicaltrials.gov\/study\/NCT00354744?term=NCT00354744&rank=1 (accessed 9 June 2025)."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.1068"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpurol.2009.06.011"},{"issue":"1","key":"e_1_3_3_11_2","first-page":"77","article-title":"[Pelvic irradiation and hematopoietic toxicity: a review of the literature]","volume":"25","author":"Kuntz L","year":"2021","unstructured":"Kuntz L, Noel G. [Pelvic irradiation and hematopoietic toxicity: a review of the literature]. Cancer Radiother J la Soc Fr Radiother Oncol 2021; 25(1): 77\u201391.","journal-title":"Cancer Radiother J la Soc Fr Radiother Oncol"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/26\/3\/003"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-024-01844-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.646211"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103497"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26061"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.992738"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.07.064"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32204"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrad069"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1088\/0031-9155\/5\/3\/302"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207591"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1088\/1752-7163\/aaacf1"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aanat.2015.09.002"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05375-6"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040722"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04926.x"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00020"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29511"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251347441","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603251347441","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251347441","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T06:23:50Z","timestamp":1774333430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603251347441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/03915603251347441"],"URL":"https:\/\/doi.org\/10.1177\/03915603251347441","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}